Genfleet Therapeutics (shanghai) Inc.
Clinical trials sponsored by Genfleet Therapeutics (shanghai) Inc., explained in plain language.
-
New targeted drug hopes to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called GFH375 in about 400 adults with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe, how the body processes it, and whether it can shrink tumors. Participants must be 18-75…
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New hope for hard-to-treat cancers: targeted combo therapy enters human trials
Disease control Recruiting nowThis study tests a new drug (GFH375) combined with either cetuximab or chemotherapy in people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if the combination is safe and can shrink tumors. About 126 adults who have not responded to standa…
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated May 07, 2026 18:42 UTC